Clinical Trials
84
Trial Phases
5 Phases
Drug Approvals
84
Drug Approvals
Lansoprazole Enteric Capsules
- Product Name
- 兰索拉唑肠溶胶囊
- Approval Number
- 国药准字HJ20250069
- Approval Date
- Jun 10, 2025
Voriconazole for Oral Suspension
- Product Name
- 伏立康唑干混悬剂
- Approval Number
- 国药准字HJ20250023
- Approval Date
- Mar 4, 2025
Dabigatran Etexilate Capsules
- Product Name
- 达比加群酯胶囊
- Approval Number
- 国药准字HJ20240155
- Approval Date
- Dec 1, 2024
Posaconazole Enteric-coated Tablets
- Product Name
- 泊沙康唑肠溶片
- Approval Number
- 国药准字HJ20240139
- Approval Date
- Dec 1, 2024
Dabigatran Etexilate Capsules
- Product Name
- 达比加群酯胶囊
- Approval Number
- 国药准字HJ20240154
- Approval Date
- Dec 1, 2024
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (78 trials with phase data)• Click on a phase to view related trials
News
Sputnik V COVID-19 Vaccine to be Produced in India with Hetero Collaboration
The Russian Direct Investment Fund (RDIF) and Hetero have agreed to produce over 100 million doses per year of the Sputnik V vaccine in India.
Dr. Reddy's and Hetero Partner with Gilead to Produce Generic HIV Drug Lenacapavir
• Dr. Reddy's and Hetero have signed non-exclusive licensing agreements with Gilead to manufacture and market generic lenacapavir in 120 countries. • Lenacapavir, marketed as Sunlenca, is approved for multi-drug resistant HIV-1 and is under investigation for HIV prevention (PrEP). • The agreement allows Dr. Reddy's to handle technology transfer, clinical studies, and product launches in the specified markets. • This collaboration aims to provide affordable access to lenacapavir in low- and middle-income countries with high HIV prevalence.